- Home
- ECOR vs PLRX Comparison
ECOR vs PLRX Comparison
Compare ECOR & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ECOR | PLRX |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.6M | 73.7M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ECOR | PLRX |
|---|---|---|
| Price | $9.50 | $1.16 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 4 |
| Target Price | ★ $18.00 | $2.67 |
| AVG Volume (30 Days) | 95.4K | ★ 390.5K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $32,032,000.00 | N/A |
| Revenue This Year | $33.60 | N/A |
| Revenue Next Year | $30.40 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 27.20 | N/A |
| 52 Week Low | $4.41 | $1.02 |
| 52 Week High | $10.95 | $1.95 |
Technical Indicators
Market Signals| Indicator | ECOR | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 56.76 | 55.26 |
| Support Level | $5.70 | $1.12 |
| Resistance Level | $10.60 | $1.26 |
| Average True Range (ATR) | 0.80 | 0.05 |
| MACD | -0.14 | 0.00 |
| Stochastic Oscillator | 43.30 | 50.00 |
Price Performance
Historical ComparisonAbout ECOR electroCore Inc.
electroCore Inc is a bioelectronic technology company whose mission is to improve health and quality of life through non-invasive bioelectronic technologies. Its two commercial products are gammaCore non-invasive vagus nerve stimulation, or nVNS, and Quell Fibromyalgia, or Quell. It also sells Truvaga and TAC-STIM products, which are handheld, personal-use consumer products developed to promote general wellness and human performance. It operates in one segment: Bioelectronic Innovations. Geographically, it operates in the United States, the United Kingdom, Japan, and Other.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.